Compare Cronos Group Inc (CRON) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs F5 Inc — how do they compare? Cronos Group Inc trades at $2.77 (market cap $1.02B), while F5 Inc trades at $426.56 (market cap $24.33B). The key difference: F5 Inc is far larger — about 23.9× Cronos Group Inc's market cap, and F5 Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | FFIV | |
|---|---|---|
Market Cap | $1.02B | $24.33B |
Sector | Health | Technology |
52-Week High | $3.27 | $431.26 |
52-Week Low | $1.95 | $223.99 |
Enterprise Value | $203.29M | $23.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
F5 Networks (FFIV) trades at $420.95, down 2.19% today, with a bullish technical signal from moving averages and strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $3.90 exceeding the $3.46 estimate. Revenue growth accelerated to $3.09 billion in 2025, while net income margins expanded to 22.42%. Recent strategic moves include expanding AI security capabilities through the SurePath AI acquisition and new executive appointments.
FFIV presents a mixed outlook with strong operational execution offset by premium valuations. The stock trades above analyst consensus target of $397, though institutional sentiment remains positive with 40% buy ratings. Key risks include competitive pressures in cybersecurity and execution challenges in AI integration. Earnings growth and margin expansion remain the primary catalysts for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
